Alembic Charts 40% US Growth Despite Loss of Bosutinib Patent Exclusivity

Alembic Pharmaceuticals is charting an ambitious growth trajectory for its American market operations, targeting approximately 40 per cent expansion in fiscal year 2027 despite headwinds from the expiration of exclusivity on Bosutinib, one of its established revenue drivers in the region.

The company is looking to offset the anticipated erosion from the loss of Bosutinib exclusivity—which allows generic versions to enter the market—through an aggressive new product introduction strategy. Alembic plans to launch around 30 new drugs in the United States during the period, focusing particularly on complex generic formulations that command higher margins and face fewer competitive pressures than standard generics.

Beyond its US operations, Alembic is also placing emphasis on enhancing sales productivity across its domestic Indian market. The dual strategy reflects the company's intent to balance growth in its international operations, particularly the lucrative American pharmaceutical sector, with strengthened performance in its home market where it competes in a crowded generics landscape.

The expansion of Alembic's US portfolio aligns with broader industry trends among Indian drugmakers seeking to mitigate patent cliff risks by maintaining a steady stream of new product approvals. Complex generics, which include modified-release formulations and difficult-to-manufacture products, are increasingly viewed as a competitive advantage in a market dominated by commoditized simple generics.